What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in progression‐free survival/time to progression (randomised… (moderate certainty).

• Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.92 [0.84, 1.01]
  13 studies · 1745 participants
  Moderate

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

The review found no eligible studies for this question.

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT

Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in progression‐free survival compared with stereotactic radiosurgery plus WBRT (low certainty).

• Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
  RR 0.55 [0.22, 1.38]
  1 study · 21 participants
  Low

Delayed chemotherapy vs immediate chemotherapy

• Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 351 participants
  Low

Irinotecan + oxaliplatin vs irinotecan

Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.6 [0.55, 0.66]
  1 study · 627 participants
  Moderate

Chemotherapy vs best supportive care

The review found no eligible studies for this question.

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Modern chemotherapy regimens vs 5‐flourouracil

Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.59 [0.49, 0.73]
  2 studies · 470 participants
  High

FOLFIRI + targeted therapy vs FOLFIRI

FOLFIRI + targeted therapy leads to lower progression‐free survival compared with FOLFIRI (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.78 [0.71, 0.87]
  6 studies · 3335 participants
  High

FOLFOX + targeted therapy vs FOLFOX

FOLFOX + targeted therapy may leads to lower progression‐free survival compared with FOLFOX (low certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.76 [0.66, 0.86]
  2 studies · 1432 participants
  Low

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.71 [0.64, 0.79]
  2 studies · 1758 participants
  Moderate

Bevacizumab plus chemotherapy vs chemotherapy alone

Chemotherapy + bevacizumab leads to lower progression‐free survival compared with chemotherapy (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.67 [0.6, 0.75]
  4 studies · 1723 participants
  High

Irinotecan‐based regimens vs irinotecan

Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.68 [0.6, 0.76]
  6 studies · 2615 participants
  Moderate

Intervention not reported

The intervention leads to lower progression‐free survival (high certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.7 [0.6, 0.82]
  12 studies · 4402 participants
  High

Intervention not reported

The intervention probably leads to lower progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.6 [0.48, 0.75]
  6 studies · 1237 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.13 [0.93, 1.36]
  6 studies · 2023 participants
  Moderate

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1483 participants
  High

Intervention not reported

The intervention showed no clear difference in progression‐free survival (high certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.02 [0.93, 1.12]
  4 studies · 2189 participants
  High

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1651 participants
  Moderate

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 181 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes progression‐free survival (very low certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.04 [0.83, 1.29]
  6 studies · 1571 participants
  Very low